Veeva Systems (NYSE:VEEV) Updates FY25 Earnings Guidance

Veeva Systems (NYSE:VEEV) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $6.22 for the period, compared to the consensus earnings per share estimate of $6.16. The company issued revenue guidance of $2.704-2.710 billion, compared to the consensus revenue estimate of $2.71 billion. Veeva Systems also updated its FY 2025 guidance to 6.220-6.220 EPS.

Analysts Set New Price Targets

Several research firms have recently commented on VEEV. Raymond James lifted their target price on Veeva Systems from $230.00 to $235.00 and gave the company an outperform rating in a research note on Thursday. Stifel Nicolaus cut their price objective on shares of Veeva Systems from $250.00 to $210.00 and set a buy rating on the stock in a report on Friday, May 31st. BTIG Research assumed coverage on shares of Veeva Systems in a report on Tuesday, July 9th. They set a buy rating and a $240.00 target price for the company. Piper Sandler raised their price target on Veeva Systems from $225.00 to $230.00 and gave the stock an overweight rating in a research report on Thursday. Finally, Robert W. Baird increased their target price on Veeva Systems from $245.00 to $251.00 and gave the company an outperform rating in a research note on Thursday. One analyst has rated the stock with a sell rating, seven have given a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of Moderate Buy and an average price target of $230.13.

Veeva Systems Price Performance

Shares of NYSE VEEV opened at $216.47 on Friday. The business has a 50-day moving average of $188.49 and a 200-day moving average of $202.13. The stock has a market capitalization of $34.99 billion, a price-to-earnings ratio of 63.86, a PEG ratio of 1.95 and a beta of 0.80. Veeva Systems has a fifty-two week low of $162.72 and a fifty-two week high of $236.90.

Veeva Systems (NYSE:VEEV) last posted its quarterly earnings results on Thursday, May 30th. The technology company reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.93 by $0.10. Veeva Systems had a return on equity of 12.74% and a net margin of 22.34%. The firm had revenue of $650.35 million during the quarter, compared to the consensus estimate of $641.73 million. On average, sell-side analysts expect that Veeva Systems will post 4.19 EPS for the current year.

Insiders Place Their Bets

In other Veeva Systems news, CFO Timothy S. Cabral sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $184.33, for a total value of $2,764,950.00. Following the sale, the chief financial officer now owns 8,391 shares in the company, valued at $1,546,713.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CFO Timothy S. Cabral sold 15,000 shares of the stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $184.33, for a total transaction of $2,764,950.00. Following the transaction, the chief financial officer now owns 8,391 shares in the company, valued at $1,546,713.03. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Jonathan Faddis sold 2,353 shares of the company’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $200.00, for a total value of $470,600.00. Following the completion of the transaction, the senior vice president now directly owns 9,035 shares in the company, valued at $1,807,000. The disclosure for this sale can be found here. Insiders own 10.50% of the company’s stock.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.